检索结果 - Kejal Parikh

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

    Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States 由 C. Pelligra, Kejal Parikh, Shien Guo, C. Chandler, Jorge Mouro, Safiya Abouzaid, Sikander Ailawadhi

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Trends in overall survival and costs of multiple myeloma, 2000–2014

    Trends in overall survival and costs of multiple myeloma, 2000–2014 由 Rafaël Fonseca, Safiya Abouzaid, Machaon Bonafede, Qizhe Cai, Kejal Parikh, Leon E. Cosler, Paul G. Richardson

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

    Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases 由 Jipan Xie, M. Namjoshi, Eric Q. Wu, Kejal Parikh, Melissa Diener, Andrew P. Yu, Amy Guo, Kenneth W. Culver

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis

    Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis 由 Sikander Ailawadhi, Kejal Parikh, Safiya Abouzaid, Zhou Zhou, Wenxi Tang, Zoe Clancy, Claudia Cheung, Zheng‐Yi Zhou, Jipan Xie

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: